Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immune Therapeutics Inc (OP: IMUN ) N/A UNCHANGED Last Price Updated: 12:27 PM EDT, Oct 18, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0930 Today's Range N/A - N/A 52wk Range 0.0668 - 0.1300 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky September 14, 2023 From Immune Therapeutics, Inc. Via GlobeNewswire Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV August 29, 2023 From Immune Therapeutics, Inc. Via GlobeNewswire Performance More News Read More Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH August 15, 2023 From Immune Therapeutics, Inc. Via GlobeNewswire Statera Biopharma Shares Fall After Taking Stake In Holographic Medical Imaging October 18, 2022 Via Benzinga Why Are Statera Biopharma Shares Surging Today April 28, 2022 Via Benzinga Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies April 20, 2023 From Immune Therapeutics, Inc. Via GlobeNewswire Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction March 01, 2023 From Immune Therapeutics, Inc. Via GlobeNewswire Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development November 09, 2022 From Immune Therapeutics, Inc. Via GlobeNewswire Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors September 27, 2022 From Immune Therapeutics, Inc. Via GlobeNewswire The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates April 28, 2022 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday April 28, 2022 Via InvestorPlace The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 December 17, 2021 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.